Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-005661
Filing Date
2021-02-10
Accepted
2021-02-10 16:15:21
Documents
2
Period of Report
2021-02-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6579
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4645
  Complete submission text file 0000899243-21-005661.txt   12536
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Issuer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address
Moxham Christopher (Reporting) CIK: 0001843784 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38978 | Film No.: 21613974